ClinicalTrials.Veeva

Menu

The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)

R

Ruhr University of Bochum

Status

Completed

Conditions

Coronary Artery Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01796691
BOCLAplan02
[Ruhr-University Bochum] (Registry Identifier)

Details and patient eligibility

About

Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

Full description

The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Enrollment

600 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • coronary stent implantation

Exclusion criteria

  • no consent

Trial design

600 participants in 2 patient groups

Standard therapy
Description:
Antiplatelet therapy following coronary stenting without platelet function testing
Optimized antiplatelet therapy
Description:
Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder. Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems